Veröffentlichungen

18 Min. Lesezeit • 3.834 Wörter

Link zur Webseite befindet sich in der Zwischenablage

Auf dieser Seite

Manuscripts under preparation

107. Magomedova Z, Rauniyar K, Hyvärinen S, Lehti T, Gąciarz A, Uotila L, et al. Use of Cas9 base editors for the affinity maturation of antibodies. manuscript in preparation;

2020s

106. Yle Uutiset [Internet]. 2026 [cited 2026 July 5]. Lapin syrjäseuduille on viime aikoina kadonnut jo kolme henkilöä – tämä tapauksista tiedetään nyt. Available from: https://yle.fi/a/74-20234684
105. Lehto S, Sima S, Künnapuu J, Iljukov S, Jeltsch M. Angiogenic Doping: Plausible Yet Difficult to Detect. Sports Med [Internet]. 2026 May 21 [cited 2026 May 21]; Available from: https://link.springer.com/10.1007/s40279-026-02447-y
104. Elbadri K, Fuscielo M, Hamdan F, Cheng R, Feola S, Bokharaie H, et al. Design and in vitro validation of Brome mosaic –virus-like particles for gene delivery and immunomodulation of melanoma. Materials Today Bio [Internet]. 2025 Dec 14 [cited 2025 Dec 27];102693. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2590006425012657
103. Udd T, Fuse R, Haris-Kiss A, Lüpke F, Jeltsch M, Duplouy A. Flamma - News. 2025 [cited 2025 Dec 15]. Teaching and supervising in Finnish. Available from: https://tinyurl.com/flamma-2025-12-10
102. Jeltsch M. Miten ihmisten ja kalojen verisuonijärjestelmät eroavat toisistaan? mene & tiedä [Internet]. 2025 Nov 12 [cited 2025 Nov 12]; Available from: https://menejatieda.fi/miten-ihmisten-ja-kalojen-verisuonijarjestelmat-eroavat-toisistaan/
101. Barbiera M, Gynther M, Terasaki T, Jauhiainen S, Laakkonen JP, Jeltsch M, et al. A disintegrin and metalloproteinase domain with thrombospondin motifs 18 (ADAMTS18) cleaves fibronectin and negatively regulates its fibrillogenesis. Journal of Biological Chemistry [Internet]. 2025 Oct 22 [cited 2025 Oct 27];110844. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0021925825026961
100. Mavali Zadeh A, Gatto E, Lettieri R, Bokharaie H, Caravella A, D’Ottavi C, et al. Biomass-derived lignin nanoparticles for the sustained delivery of vascular endothelial growth factor-C. European Journal of Pharmaceutics and Biopharmaceutics [Internet]. 2025 Sept 12 [cited 2025 Sept 16];216:114860. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0939641125002371
99. Brokemper J, Biti A, Jeltsch M, Sarparanta M. Towards Site-Specific Enzymatic Radiofluorination of Biomacromolecules Using Pentamutant S. aureus SrtA with Sulfur(VI)-Fluoride Exchange (SuFEx) Radiolabeled Substrates. Nuclear Medicine and Biology [Internet]. 2025 Sept 1 [cited 2026 Jan 3];148–149:109074. Available from: https://www.sciencedirect.com/science/article/pii/S0969805125000836
98. Chen G, Bokharaie H, Sima S, Kulsum U, Islam MT, Künnapuu J, et al. Why Antiangiogenic Cancer Therapies Succeed in Mice but Fail in Humans [Internet]. Poster presentation presented at; 2025 May 24. Available from: https://www.genecellnano.fi/genecellnano-4th-annual-meeting-24-25-4-2025/
97. Reunanen S, Ghemtio L, Patel JZ, Patel DR, Airavaara K, Yli-Kauhaluoma J, et al. Targeting Bacterial and Human Levodopa Decarboxylases for Improved Drug Treatment of Parkinson’s Disease: Discovery and Characterization of New Inhibitors. European Journal of Pharmaceutical Sciences [Internet]. 2025 May 20 [cited 2025 May 22];107133. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0928098725001320
96. Iqbal S, Andersson S, Nesta E, Pentinmikko N, Kumar A, Kumar Jha S, et al. Fetal-like reversion in the regenerating intestine is regulated by mesenchymal asporin. Cell Stem Cell [Internet]. 2025 Mar 6 [cited 2025 Apr 6];32(4):613-626.e8. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1934590925000487
95. Barbiera M, Beter M, Laakkonen JP, Jeltsch M, Ylä-Herttuala S, Laham-Karam N. Investigating the role of ADAMTS18 in angiogenesis. In: Human Gene Therapy [Internet]. Rome, Italy: Mary Ann Liebert; 2025. p. e256. Available from: https://www.liebertpub.com/doi/pdf/10.1089/hum.2024.63331.oab
94. Niemelä A, Giorgi L, Nouri S, Yurttaş B, Rauniyar K, Jeltsch M, et al. Gliflozins, sucrose and flavonoids are allosteric activators of lecithin-cholesterol acyltransferase. Sci Rep [Internet]. 2024 Oct 30 [cited 2024 Nov 27];14(1):26085. Available from: https://www.nature.com/articles/s41598-024-77104-3
93. Lisina S, Özliseli E, Rauniyar K, Sandholm J, Jeltsch M, Rosenholm J. Mesoporous silica-based nanocarriers with vascular endothelial growth factor embedded into the 3D printed gelatin hydrogel scaffold as a model system for preserving protein activity. In: Today’s science, tomorrow’s healthcare [Internet]. Tartu, Estonia; 2024. p. 141–3. Available from: https://bbbb2024.org/userfiles/bbbb2024/bbbb_abstract_book_2024.pdf
92. Jeltsch M. What do we really know about lipedema? In: 3 Swiss Lymphsymposium: Edema meets Obesity [Internet]. Zürich: Zenodo; 2024. Available from: https://doi.org/10.5281/zenodo.14286864
91. Panara V, Varaliová Z, Wilting J, Koltowska K, Jeltsch M. The relationship between the secondary vascular system and the lymphatic vascular system in fish. Biological Reviews [Internet]. 2024 June 28 [cited 2024 Nov 27];99(6):2108–33. Available from: https://onlinelibrary.wiley.com/doi/10.1111/brv.13114
90. López-Cerdá S, Molinaro G, Tello RP, Correia A, Künig S, Steinberger P, et al. Study of the Synergistic Immunomodulatory and Antifibrotic Effects of Dual-Loaded Budesonide and Serpine1 siRNA Lipid–Polymer Nanoparticles Targeting Macrophage Dysregulation in Tendinopathy. ACS Appl Mater Interfaces [Internet]. 2024 Apr 17;16(15):18643–57. Available from: https://doi.org/10.1021/acsami.4c02363
89. Rauniyar K. VEGF-C: The evolutionary origin, activation, and potential as a drug target [Internet] [Doctoral Thesis]. [Helsinki. Finland]: University of Helsinki; 2023. Available from: http://hdl.handle.net/10138/357923
88. Rauniyar K, Bokharaie H, Jeltsch M. Expansion and collapse of VEGF diversity in major clades of the animal kingdom. Angiogenesis [Internet]. 2023 Apr 5 [cited 2023 July 20];26(3):437–61. Available from: https://link.springer.com/10.1007/s10456-023-09874-9
87. Rauniyar K, Akhondzadeh S, Gąciarz A, Künnapuu J, Jeltsch M. Bioactive VEGF-C from E. coli. Sci Rep [Internet]. 2022 Oct 28;12(1):18157. Available from: https://doi.org/10.1038/s41598-022-22960-0
86. Jeltsch M, Alitalo K. Lymphatic-to-blood vessel transdifferentiation in zebrafish. Nat Cardiovasc Res [Internet]. 2022 May 25 [cited 2022 May 26];1:539–41. Available from: https://rdcu.be/cOjJ0
85. Koistinen H, Künnapuu J, Jeltsch M. KLK3 in the Regulation of Angiogenesis—Tumorigenic or Not? IJMS [Internet]. 2021 Dec 17 [cited 2021 Dec 22];22(24):13545. Available from: https://www.mdpi.com/1422-0067/22/24/13545
84. Jeltsch M. Drug-induced lymphangiogenesis. In: 3 Swiss Lymphsymposium: Secondary Lymhphoedema [Internet]. Zürich: Juzo; 2021. Available from: https://doi.org/10.5281/zenodo.6034307
83. Künnapuu J, Jeltsch M. Outside in and brakes off for lymphatic growth. Sci Signal [Internet]. 2021 Aug 10 [cited 2021 Aug 16];14(695):eabj5058. Available from: https://www.science.org/stoken/author-tokens/ST-1754/full
82. Künnapuu J, Bokharaie H, Jeltsch M. Proteolytic Cleavages in the VEGF Family: Generating Diversity among Angiogenic VEGFs, Essential for the Activation of Lymphangiogenic VEGFs. Biology [Internet]. 2021 Feb 23 [cited 2021 Mar 10];10(2):167. Available from: https://www.mdpi.com/2079-7737/10/2/167
81. Fang S, Chen S, Nurmi H, Leppänen VM, Jeltsch M, Scadden D, et al. VEGF-C protects the integrity of the bone marrow perivascular niche in mice. Blood [Internet]. 2020 Oct 15;136(16):1871–83. Available from: https://doi.org/10.1182/blood.2020005699
80. Gucciardo E, Lehti TA, Korhonen A, Salvén P, Lehti K, Jeltsch M, et al. Lymphatics and the eye. [Finnish]. Duodecim [Internet]. 2020 Aug 26;136(16):1777–88. Available from: https://www.duodecimlehti.fi/lehti/2020/16/duo15739
79. Mukenge S, Jha SK, Catena M, Manara E, Leppänen VM, Lenti E, et al. Investigation on the Role of Biallelic Variants in VEGF-C Found in a Patient Affected by Milroy-like Lymphedema. Mol Genet Genom Med [Internet]. 2020 June 26;8(9):e1389. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/mgg3.1389
78. Jha SK. Mechanism of VEGF-C Activation and Effect on Lymphatic Vessel Growth and Regeneration [Internet] [Doctoral Thesis]. [Helsinki, Finland]: Helsingin yliopisto; 2020 [cited 2020 June 1]. Available from: https://helda.helsinki.fi/handle/10138/314714

2010s

77. Lackner M, Schmotz C, Jeltsch M. The Proteolytic Activation of Vascular Endothelial Growth Factor-C. LymphForsch [Internet]. 2019 Dec 18;23(2):88–98. Available from: https://doi.org/10.5281/zenodo.3629263
76. Jha SK, Rauniyar K, Chronowska E, Mattonet K, Maina EW, Koistinen H, et al. KLK3/PSA and cathepsin D activate VEGF-C and VEGF-D. eLife [Internet]. 2019 May 17 [cited 2019 May 18];8:e44478. Available from: https://elifesciences.org/articles/44478
75. Jha SK, Rauniyar K, Jeltsch M. Key molecules in lymphatic development, function, and identification. Ann Anat [Internet]. 2018 Sept 1 [cited 2018 June 8];219:25–34. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0940960218300712
74. Jeltsch M. Was man in der Lymphologie über VEGF-C wissen sollte [What you need to know as a lymphologist about VEGF-C]. Vasomed [Internet]. 2018 July 1;30(4):172–3. Available from: https://www.der-niedergelassene-arzt.de/suche/ergebnis/suche/was-man-in-der-lymphologie-ueber-vegf-c-wissen-sollte
73. Rauniyar K, Jha SK, Jeltsch M. Biology of Vascular Endothelial Growth Factor C in the Morphogenesis of Lymphatic Vessels. Front Bioeng Biotechnol [Internet]. 2018 Feb 12 [cited 2018 Feb 12];6:7. Available from: https://doi.org/10.3389/fbioe.2018.00007
72. Jha SK, Rauniyar K, Karpanen T, Leppänen VM, Brouillard P, Vikkula M, et al. Efficient activation of the lymphangiogenic growth factor VEGF-C requires the C-terminal domain of VEGF-C and the N-terminal domain of CCBE1. Sci Rep [Internet]. 2017 July 7 [cited 2017 July 7];7(1):4916. Available from: https://www.nature.com/articles/s41598-017-04982-1
71. Batchu KC, Hänninen S, Jha SK, Jeltsch M, Somerharju P. Factors regulating the substrate specificity of cytosolic phospholipase A2-alpha in vitro. BBA-Mol Cell Biol L [Internet]. 2016 July 1 [cited 2016 Aug 19];1861(11):1597–604. Available from: http://www.sciencedirect.com/science/article/pii/S1388198116301743
70. Johns SC, Yin X, Jeltsch M, Bishop JR, Schuksz M, Ghazal RE, et al. Functional Importance of a Proteoglycan Co-Receptor in Pathologic Lymphangiogenesis. Circ Res [Internet]. 2016 May 25 [cited 2016 June 8];119(2):210–21. Available from: http://circres.ahajournals.org/content/early/2016/05/25/CIRCRESAHA.116.308504
69. Jeltsch M. From Molecular Genetics and Biology to Effective Treatments of Lymphatic Disorders. In: The European Journal of Lymphology and Related Problems [Internet]. Mulhouse, France; 2016. p. 11. Available from: http://www.eurolymphology.org/JOURNAL/VOL28-N74-2016/#p=14
68. Schaupper MV, Jeltsch M, Rohringer S, Redl H, Holnthoner W. Lymphatic Vessels in Regenerative Medicine and Tissue Engineering. Tissue Eng Pt B-Rev [Internet]. 2016 May 3 [cited 2016 June 8];22(5):1–13. Available from: http://online.liebertpub.com/doi/10.1089/ten.TEB.2016.0034
67. Dashkevich A, Raissadati A, Syrjälä SO, Zarkada G, Keränen MAI, Tuuminen R, et al. Ischemia-Reperfusion Injury Enhances Lymphatic Endothelial VEGFR3 and Rejection in Cardiac Allografts: Lymphatic Endothelial VEGFR3 Controls Rejection. Am J Transplant [Internet]. 2016 Mar 22 [cited 2015 Dec 22];16(4):1160–72. Available from: http://doi.wiley.com/10.1111/ajt.13564
66. Mattonet K, Jeltsch M. Heterogeneity of the origin of the lymphatic system. [German]. Lymphforsch [Internet]. 2015 Dec 1;19(2):84–8. Available from: http://www.dglymph.de/fileadmin/global/pdfs/LymphForsch_2-15.pdf
65. Mattonet K, Wilting J, Jeltsch M. Die genetischen Ursachen des primären Lymphödems. In: Weissleder H, Schuchhardt C, editors. Erkrankungen des Lymphgefäßsystems [Internet]. 6. Cologne, Germany: Viavital Verlag; 2015. p. 210–29. Available from: https://www.der-niedergelassene-arzt.de/fileadmin/user_upload/Buecher/Leseproben/Leseprobe_Kap._5.10_Erkr._Lymph_6.pdf
64. Jeltsch M. Lymphangiogenesis in Health and Disease. In: The European Journal of Lymphology and Related Problems [Internet]. Lausanne, Switzerland; 2015. p. 8. Available from: http://www.eurolymphology.org/JOURNAL/VOL26-N72-2015/#p=10
63. Roukens MG, Peterson-Maduro J, Padberg Y, Jeltsch M, Leppänen VM, Bos FL, et al. Functional Dissection of the CCBE1 Protein. A Crucial Requirement for the Collagen Repeat Domain. Circ Res [Internet]. 2015 May 8 [cited 2015 June 15];116(10):1660–9. Available from: http://circres.ahajournals.org/content/116/10/1660
62. Uusitalo E. Improvement of the quality of insect-cell-derived, recombinant pro-VEGF-C [Internet] [Bachelor’s Thesis]. [Helsinki, Finland]: Metropolia University of Applied Sciences; 2015. Available from: http://urn.fi/URN:NBN:fi:amk-201505198960
61. Batchu KC, Hokynar K, Jeltsch M, Mattonet K, Somerharju P. Substrate Efflux Propensity Is the Key Determinant of Ca2+-independent Phospholipase A-β (iPLAβ)-mediated Glycerophospholipid Hydrolysis. J Biol Chem [Internet]. 2015 Apr 17 [cited 2015 June 15];290(16):10093–103. Available from: http://www.jbc.org/content/290/16/10093
60. Saharinen P, Jeltsch M, Santoyo MM, Leppänen VM, Alitalo K. The TIE Receptor Family. In: Wheeler DL, Yarden Y, editors. Receptor Tyrosine Kinases: Family and Subfamilies [Internet]. Springer International Publishing; 2015. p. 743–75. Available from: http://dx.doi.org/10.1007/978-3-319-11888-8_16
59. Jeltsch M, Jha SK, Tvorogov D, Anisimov A, Leppänen VM, Holopainen T, et al. CCBE1 Enhances Lymphangiogenesis via A Disintegrin and Metalloprotease With Thrombospondin Motifs-3–Mediated Vascular Endothelial Growth Factor-C Activation. Circulation [Internet]. 2014 May 13 [cited 2014 May 31];129(19):1962–71. Available from: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.113.002779
58. Jha SK. CCBE1 enhances lymphangiogenesis via ADAMTS3-mediated VEGF-C processing [Internet] [Master’s Thesis]. [Helsinki, Finland]: University of Helsinki; 2014. Available from: http://hdl.handle.net/10138/155647
57. Jeltsch M. The disease they call fat - scientist/researcher episode 9: Michael Jeltsch [Internet]. 2014 [cited 2019 May 3]. Available from: https://diseasetheycallfat.lipedemaproject.org/product-tag/michael-jeltsch/
56. Krebs R, Lackner M, Jeltsch M. The lymphangiogenic growth factors VEGF-C and VEGF-D. Part 2: The role of VEGF-C and VEGF-D in lymphatic system diseases. Vasomed [Internet]. 2014 Feb 1;26(1):48–50. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-84894475851&partnerID=40&md5=abbb403b9e5e11e8cd9b93b8d4daeb0a
55. Krebs R, Jeltsch M. Die lymphangiogenen Wachstumsfaktoren VEGF-C und VEGF-D. Teil 2. Die Rolle von VEGF-C und VEGF-D bei Krankheiten des Lymphgefäßsystems. LymphForsch [Internet]. 2013 Dec 1;17(2):96–104. Available from: http://jeltsch.org/sites/jeltsch.org/files/JeltschMichael_Lymphforsch2013_96.pdf
54. Jeltsch M, Leppanen VM, Saharinen P, Alitalo K. Receptor Tyrosine Kinase-Mediated Angiogenesis. CSH Perspect Biol [Internet]. 2013 Sept 3 [cited 2013 Sept 6];5(9):a009183–a009183. Available from: http://cshperspectives.cshlp.org/lookup/doi/10.1101/cshperspect.a009183
53. Leppänen VM, Tvorogov D, Kisko K, Prota AE, Jeltsch M, Anisimov A, et al. Structural and mechanistic insights into VEGF receptor 3 ligand binding and activation. PNAS [Internet]. 2013 Aug 6 [cited 2013 Dec 18];110(32):12960–5. Available from: http://www.pnas.org/content/110/32/12960
52. Anisimov A, Leppanen VM, Tvorogov D, Zarkada G, Jeltsch M, Holopainen T, et al. The Basis for the Distinct Biological Activities of Vascular Endothelial Growth Factor Receptor-1 Ligands. Sci Signal [Internet]. 2013 July 2 [cited 2014 Jan 8];6(282):ra52. Available from: http://stke.sciencemag.org/content/6/282/ra52
51. Krebs R, Jeltsch M. Die lymphangiogenen Wachstumsfaktoren VEGF-C und VEGF-D. Teil 1. Grundlagen und Embryonalentwicklung. LymphForsch [Internet]. 2013 June 1;17(1):30–7. Available from: http://jeltsch.org/sites/jeltsch.org/files/JeltschMichael_Lymphforsch2013_30.pdf
50. Krebs R, Jeltsch M. The lymphangiogenic growth factors VEGF-C and VEGF-D. Part 1: Fundamentals and embryonic development. Vasomed [Internet]. 2013 June 1;25(6):335–6. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-84891428885&partnerID=40&md5=72c1a2e9a50f7206f427bfb42e59bda3
49. Anisimov A, Tvorogov D, Alitalo A, Leppänen VM, An Y, Han EC, et al. Vascular Endothelial Growth Factor-Angiopoietin Chimera With Improved Properties for Therapeutic AngiogenesisClinical Perspective. Circulation [Internet]. 2013 Jan 29 [cited 2013 Apr 4];127(4):424–34. Available from: http://circ.ahajournals.org/content/127/4/424
48. Villefranc JA, Nicoli S, Bentley K, Jeltsch M, Zarkada G, Moore JC, et al. A truncation allele in vascular endothelial growth factor c reveals distinct modes of signaling during lymphatic and vascular development. Development [Internet]. 2013 Jan 23;140(7):1497–506. Available from: http://dx.doi.org/10.1242/dev.084152
47. Krebs R, Tikkanen JM, Ropponen JO, Jeltsch M, Jokinen JJ, Yla-Herttuala S, et al. Critical Role of VEGF-C/VEGFR-3 Signaling in Innate and Adaptive Immune Responses in Experimental Obliterative Bronchiolitis. Am J Pathol [Internet]. 2012 Sept 10;181(5):1607–20. Available from: http://ajp.amjpathol.org/article/S0002-9440(12)00589-5/fulltext
46. Alitalo K, Jeltsch MM, Leppänen VM, Aho K, Anisimov A, Tvorogov D. VEGFR-2-specific forms of VEGF-D and VEGF-C and uses thereof [Internet]. WO2012088563-A1, 2012. Available from: https://patentimages.storage.googleapis.com/14/9c/63/7491c59c0c3533/WO2012088563A1.pdf
45. Krebs R, Tikkanen JM, Ropponen JO, Jeltsch M, Jokinen JJ, Yla-Herttuala S, et al. VEGF-C/VEGFR-3 Signaling Regulates Inflammatory Response in Development of Obliterative Airway Disease. J Heart Lung Transpl [Internet]. 2011 Mar 21;30(4):S118–S118. Available from: http://dx.doi.org/10.1016/j.healun.2011.01.348
44. Leppänen VM, Jeltsch M, Anisimov A, Tvorogov D, Aho K, Kalkkinen N, et al. Structural determinants of vascular endothelial growth factor-D receptor binding and specificity. Blood [Internet]. 2011 Feb 3 [cited 2012 Sept 22];117(5):1507–15. Available from: http://dx.doi.org/10.1182/blood-2010-08-301549
43. Tvorogov D, Anisimov A, Zheng W, Leppänen VM, Tammela T, Laurinavicius S, et al. Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization. Cancer Cell [Internet]. 2010 Dec 14 [cited 2012 Feb 23];18(6):630–40. Available from: http://dx.doi.org/10.1016/j.ccr.2010.11.001
42. Albrecht I, Kopfstein L, Strittmatter K, Schomber T, Falkevall A, Hagberg CE, et al. Suppressive Effects of Vascular Endothelial Growth Factor-B on Tumor Growth in a Mouse Model of Pancreatic Neuroendocrine Tumorigenesis. PLoS ONE [Internet]. 2010 Nov 24;5(11):e14109. Available from: http://dx.doi.org/10.1371/journal.pone.0014109
41. Bry M, Kivelä R, Holopainen T, Anisimov A, Tammela T, Soronen J, et al. Vascular Endothelial Growth Factor-B Acts as a Coronary Growth Factor in Transgenic Rats Without Inducing Angiogenesis, Vascular Leak, or Inflammation. Circulation [Internet]. 2010 Oct 26 [cited 2015 Apr 30];122(17):1725–33. Available from: http://circ.ahajournals.org/content/122/17/1725
40. Saharinen P, Helotera H, Miettinen J, Norrmen C, D’Amico G, Jeltsch M, et al. Claudin-like protein 24 interacts with the VEGFR-2 and VEGFR-3 pathways and regulates lymphatic vessel development. Gene Dev [Internet]. 2010 Mar 5;24(9):875–80. Available from: http://dx.doi.org/10.1101/gad.565010
39. Leppänen VM, Prota AE, Jeltsch M, Anisimov A, Kalkkinen N, Strandin T, et al. Structural determinants of growth factor binding and specificity by VEGF receptor 2. PNAS [Internet]. 2010 Feb 9 [cited 2012 Sept 22];107(6):2425–30. Available from: http://www.pnas.org/content/107/6/2425

2000s

38. Anisimov A, Alitalo A, Korpisalo P, Soronen J, Kaijalainen S, Leppänen VM, et al. Activated Forms of VEGF-C and VEGF-D Provide Improved Vascular Function in Skeletal Muscle. Circ Res [Internet]. 2009 June 5 [cited 2012 Sept 15];104(11):1302–12. Available from: http://circres.ahajournals.org/content/104/11/1302
37. Karpanen T, Bry M, Ollila HM, Seppanen-Laakso T, Liimatta E, Leskinen H, et al. Overexpression of Vascular Endothelial Growth Factor-B in Mouse Heart Alters Cardiac Lipid Metabolism and Induces Myocardial Hypertrophy. Circ Res [Internet]. 2008 Oct 24;103(9):1018-U247. Available from: https://doi.org/10.1161%2FCIRCRESAHA.108.178459
36. Li X, Tjwa M, Van Hove I, Enholm B, Neven E, Paavonen K, et al. Reevaluation of the role of VEGF-B suggests a restricted role in the revascularization of the ischemic myocardium. Arterioscler Thromb Vasc Biol [Internet]. 2008 Sept 1 [cited 2012 Feb 23];28(9):1614–20. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18511699
35. Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Yla-Herttuala S, et al. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res [Internet]. 2008 June 1;68(12):4754–62. Available from: http://dx.doi.org/10.1158/0008-5472.CAN-07-5809
34. Keskitalo S, Tammela T, Lyytikka J, Karpanen T, Jeltsch M, Markkanen J, et al. Enhanced Capillary Formation Stimulated by a Chimeric Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor-C Silk Domain Fusion Protein. Circ Res [Internet]. 2007 May 25 [cited 2012 Feb 22];100(10):1460–7. Available from: http://circres.ahajournals.org/content/100/10/1460
33. Tammela T, He Y, Lyytikkä J, Jeltsch M, Markkanen J, Pajusola K, et al. Distinct Architecture of Lymphatic Vessels Induced by Chimeric Vascular Endothelial Growth Factor-C/Vascular Endothelial Growth Factor Heparin-Binding Domain Fusion Proteins. Circ Res [Internet]. 2007 May 25 [cited 2012 Feb 22];100(10):1468–75. Available from: http://circres.ahajournals.org/content/100/10/1468
32. Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Wedge SR, et al. Inhibition of VEGF-C-induced VEGFR-3 activity and lymphatic endothelial cell function by the tyrosine kinase inhibitor AZD2171. In: Proc AACR Ann Meet [Internet]. Los Angeles, CA: American Association for Cancer Research; 2007. p. 2999. Available from: http://cancerres.aacrjournals.org/content/67/9_Supplement/2999
31. Aho K. Production and Purification of Recombinant Human Vascular Endothelial Growth Factor D [Internet] [Master’s Thesis]. [Helsinki. Finland]: University of Helsinki; 2006. Available from: https://helda.helsinki.fi/handle/10138/29574
30. Karpanen T, Heckman CA, Keskitalo S, Jeltsch M, Ollila H, Neufeld G, et al. Functional interaction of VEGF-C and VEGF-D with neuropilin receptors. FASEB J [Internet]. 2006 July 1 [cited 2012 Dec 20];20(9):1462–72. Available from: http://www.fasebj.org/content/20/9/1462
29. Jeltsch M, Karpanen T, Strandin T, Aho K, Lankinen H, Alitalo K. Vascular Endothelial Growth Factor (VEGF)/VEGF-C Mosaic Molecules Reveal Specificity Determinants and Feature Novel Receptor Binding Patterns. J Biol Chem [Internet]. 2006 Feb 27 [cited 2014 May 19];281(17):12187–95. Available from: http://www.jbc.org/content/281/17/12187
28. Jeltsch, Michael, Alitalo, Kari. VEGF Receptors. In: Watling, K., editor. Sigma-RBI Handbook of Receptor Classification and Signal Transduction [Internet]. 5. Sigma-Aldrich Co. LLC; 2006. p. 338–9. Available from: https://jeltsch.org/sites/jeltsch.org/files/JeltschMichael_Sigma-RBI2006_338.pdf
27. He YL, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S, et al. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res [Internet]. 2005 June 1;65(11):4739–46. Available from: http://dx.doi.org/10.1158/0008-5472.CAN-04-4576
26. Krebs R, Tikkanen JM, Nykanen AI, Wood J, Jeltsch M, Yla-Herttuala S, et al. Dual role of vascular endothelial growth factor in experimental obliterative bronchiolitis. Am J Resp Crit Care [Internet]. 2005 Mar 15;171(12):1421–9. Available from: http://dx.doi.org/ 10.1164/rccm.200408-1001OC
25. Baluk P, Tammela T, Ator E, Lyubynska N, Achen MG, Hicklin DJ, et al. Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. J Clin Invest [Internet]. 2005 Feb 1 [cited 2012 Sept 15];115(2):247–57. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC544601/
24. Karkkainen MJ, Haiko P, Sainio K, Partanen J, Taipale J, Petrova TV, et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol [Internet]. 2004 Jan 1 [cited 2012 Sept 15];5(1):74–80. Available from: http://dx.doi.org/10.1038/ni1013
23. Veikkola T, Lohela M, Ikenberg K, Makinen T, Korff T, Saaristo A, et al. Intrinsic versus micro environmental regulation of lymphatic endothelial cell phenotype and function. FASEB J [Internet]. 2003 Nov 1;17(14):2006–13. Available from: http://dx.doi.org/10.1096/fj.03-0179com
22. Jeltsch M, Tammela T, Alitalo K, Wilting J. Genesis and pathogenesis of lymphatic vessels. Cell Tissue Res [Internet]. 2003 Aug 27;314(1):69–84. Available from: http://dx.doi.org/10.1007/s00441-003-0777-2
21. Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol [Internet]. 2003 June 16;161(6):1163–77. Available from: http://dx.doi.org/
20. Jeltsch M. VEGFR-3 Ligands and Lymphangiogenesis [Internet] [Doctoral Thesis]. [Helsinki, Finland]: University of Helsinki; 2002. Available from: http://urn.fi/URN:ISBN:952-10-0652-8
19. Saaristo A, Veikkola T, Enholm B, Hytonen M, Arola J, Pajusola K, et al. Adenoviral VEGF-C overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes. FASEB J [Internet]. 2002 July 1;16(9):1041–9. Available from: http://dx.doi.org/10.1096/fj.01-1042com
18. Laakkonen T. Recombinant Production of N-glycosylated VEGF-B [Internet] [Bachelor’s Thesis]. [Helsinki, Finland]: Espoo-Vantaa Institute of Technology; 2001. Available from: https://www.researchgate.net/publication/281834791_Recombinant_Production_of_N-glycosylated_VEGF-B
17. Jussila L, Veikkola T, Jeltsch M, Thurston G, McDonald D, Achen M, et al. Signalling via VEGFR-3 is sufficient for lymphangiogenesis in transgenic mice. In: Clinical Cancer Research [Internet]. Miami Beach, Florida; 2001. p. 3762S-3762S. Available from: https://jeltsch.org/sites/jeltsch.org/files/Jussila_et_al_CCR_Supplement.pdf
16. Enholm B, Karpanen T, Jeltsch M, Kubo H, Stenback F, Prevo R, et al. Adenoviral Expression of Vascular Endothelial Growth Factor-C Induces Lymphangiogenesis in the Skin. Circulation Research [Internet]. 2001 Mar 30 [cited 2017 May 3];88(6):623–9. Available from: https://www.ahajournals.org/doi/10.1161/01.RES.88.6.623
15. Veikkola T, Jussila L, Makinen T, Karpanen T, Jeltsch M, Petrova TV, et al. Signalling via vascular endothelial growth factor receptor‐3 is sufficient for lymphangiogenesis in transgenic mice. The EMBO Journal [Internet]. 2001 Mar 15 [cited 2015 June 15];20(6):1223–31. Available from: http://dx.doi.org/10.1093/emboj/20.6.1223
14. Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, Prevo R, et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J [Internet]. 2001 Feb 15;20(4):672–82. Available from: http://emboj.embopress.org/content/20/4/672
13. Hiltunen MO, Laitinen M, Turunen MP, Jeltsch M, Hartikainen J, Rissanen TT, et al. Intravascular adenovirus-mediated VEGF-C gene transfer reduces neointima formation in balloon-denuded rabbit aorta. Circulation [Internet]. 2000 Oct 13;102(18):2262–8. Available from: http://dx.doi.org/10.1161/01.CIR.102.18.2262
12. Hiltunen MO, Laitinen M, Turunen MP, Jeltsch M, Hartikainen J, Rissanen TT, et al. VEGF-C adenovirus gene transfer reduces intima formation in rabbits. In: Atherosclerosis [Internet]. Stockholm, Sweden; 2000 [cited 2015 Feb 26]. p. 81. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0021915000803664

1990s

11. Olofsson B, Jeltsch M, Eriksson U, Alitalo K. Current biology of VEGF-B and VEGF-C. Curr Opin Biotech [Internet]. 1999 Dec 1;10(6):528–35. Available from: http://dx.doi.org/10.1016/S0958-1669(99)00024-5
10. Pepper MS, Mandriota SJ, Jeltsch M, Kumar V, Alitalo K. Vascular endothelial growth factor (VEGF)-C synergizes with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity. J Cell Physiol [Internet]. 1998 Dec 1 [cited 2015 Apr 30];177(3):439–52. Available from: http://onlinelibrary.wiley.com/doi/10.1002/(SICI)1097-4652(199812)177:3<439::AID-JCP7>3.0.CO;2-2/abstract
9. Olofsson B, Korpelainen E, Pepper MS, Mandriota SJ, Aase K, Kumar V, et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. PNAS [Internet]. 1998 Sept 29 [cited 2015 Apr 30];95(20):11709–14. Available from: http://www.pnas.org/content/95/20/11709
8. Achen MG, Jeltsch M, Kukk E, Mäkinen T, Vitali A, Wilks AF, et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). PNAS [Internet]. 1998 Jan 20 [cited 2012 Sept 15];95(2):548–53. Available from: http://www.pnas.org/content/95/2/548
7. Joukov V, Kaipainen A, Jeltsch M, Pajusola K, Olofsson B, Kumar V, et al. Vascular endothelial growth factors VEGF-B and VEGF-C. J Cell Physiol [Internet]. 1997 Nov 1;173(2):211–5. Available from: http://dx.doi.org/10.1002/(SICI)1097-4652(199711)173:2<211::AID-JCP23>3.0.CO;2-H
6. Chilov D, Kukk E, Taira S, Jeltsch M, Kaukonen J, Palotie A, et al. Genomic organization of human and mouse genes for vascular endothelial growth factor C. J Biol Chem [Internet]. 1997 Oct 3;272(40):25176–83. Available from: http://dx.doi.org/10.1074/jbc.272.40.25176
5. Oh SJ, Jeltsch MM, Birkenhäger R, McCarthy JEG, Weich HA, Christ B, et al. VEGF and VEGF-C: Specific Induction of Angiogenesis and Lymphangiogenesis in the Differentiated Avian Chorioallantoic Membrane. Dev Biol [Internet]. 1997 Aug 1 [cited 2012 Sept 22];188(1):96–109. Available from: http://dx.doi.org/10.1006/dbio.1997.8639
4. Joukov V, Sorsa T, Kumar V, Jeltsch M, Claesson-Welsh L, Cao Y, et al. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J [Internet]. 1997 July 1 [cited 2012 Aug 22];16(13):3898–911. Available from: http://dx.doi.org/10.1093/emboj/16.13.3898
3. Jeltsch M, Kaipainen A, Joukov V, Meng X, Lakso M, Rauvala H, et al. Hyperplasia of Lymphatic Vessels in VEGF-C Transgenic Mice. Science [Internet]. 1997 May 30 [cited 2012 Sept 22];276(5317):1423–5. Available from: http://dx.doi.org/10.1126/science.276.5317.1423
2. Jeltsch M. Functional Analysis of VEGF-B and VEGF-C [Internet] [Master’s Thesis]. [Helsinki, Finland]: University of Helsinki; 1997. Available from: http://urn.fi/URN:NBN:fi-fe977347
1. Kukk E, Lymboussaki A, Taira S, Kaipainen A, Jeltsch M, Joukov V, et al. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development [Internet]. 1996 Dec 1;122(12):3829–37. Available from: http://dev.biologists.org/content/122/12/3829.long